Active Idiopathic Inflammatory Myopathy

Current Clinical Trial

Name:

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm,

Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability,
Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in
Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy

Description:

This study’s purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM).
Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Further Information

Stage:

Recruiting

Principal Investigator:

Professor Eamonn Molloy

Sponsor:

Argenx

Network Partners